Navigation Links
InterMune Reports Third Quarter 2010 Financial Results
Date:10/28/2010

third quarter of 2010, compared with $9.9 million in the same period a year earlier, an increase of 10 percent.  G&A expenses were $38.7 million in the first nine months of 2010, an increase of 44 percent from $26.9 million in 2009.  The higher G&A expenses are primarily attributed to costs related to preparation for the potential U.S. commercialization of pirfenidone in 2010, which did not occur.  

The net loss for the third quarter of 2010 was $24.3 million, or $0.44 per share, compared with a net loss of $8.8 million, or $0.19 per share, in the third quarter of 2009.  Net loss for the first nine months of 2010 was $83.7 million, or $1.55 per share, compared with a net loss of $87.4 million, or $2.00 per share, in the comparable period of 2009.As of September 30, 2010, InterMune had cash, cash equivalents and available-for-sale securities of approximately $133.5 million, which does not include net proceeds of $175.0 million from the company's sale to Roche of worldwide development and commercialization rights for danoprevir, announced on October 6, 2010.

Guidance for 2010 Expenses  The company today provided updated financial guidance from that initially provided on July 27, 2010, for operating expenses in 2010.

Operating Expenses

  • R&D expense:  anticipated to be between $65 and $70 million, compared to the company's previous guidance of between $80 and $90 million.
  • G&A expense:  anticipated to be between $45 and $50 million, compared to the company's previous guidance of between $40 and $50 million.  

  • Revenue: InterMune is not providing full-year 2010 revenue guidance for the company at this time as the final determination has not yet been made regarding the accounting treatment for the transaction in which InterMune sold worldwide development and commercialization rights for danoprevir to Roche on October 6, 2010.Conference
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
    2. InterMune to Release Second Quarter Financial Results on July 27
    3. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
    4. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
    5. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
    6. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
    7. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
    8. InterMune to Present at Deutsche Bank Biotech Confab
    9. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
    10. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
    11. InterMune to Present at JMP Securities Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
    (Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
    (Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
    Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
    ... Perrigo Company (Nasdaq: PRGO ; ... Cooperation and License agreements with Brilite Nutritionals (Shanghai) ... company. Under these agreements, Perrigo will supply its ... will exclusively source all its infant formula requirements ...
    ... and HERZLIYA PITUACH, Israel, Nov. 8, 2011 ... -- SMT Research & Development, Ltd. ("SMT") ... as Vice President and General Manager.  Mr. Porath will ... company,s development and production facility in Herzliya Pituach, Israel, ...
    Cached Medicine Technology:Perrigo Expands Infant Formula Distribution in China With Brilite Nutritionals (Shanghai) Co., Ltd. 2SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence 2SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence 3
    (Date:8/30/2015)... , ... August 31, 2015 , ... ... and a third of tax receipts, issues that are critically important to them ... bands of attorneys and lobbyists monitoring proposed legislation and changing tax and regulatory ...
    (Date:8/30/2015)... (PRWEB) , ... August 31, 2015 , ... ... Magazine: The Fun Cooking Magazine for Kids , recently elected two new officers ... These appointments will further ChopChop’s mission of inspiring and teaching kids to cook ...
    (Date:8/30/2015)... ... August 30, 2015 , ... ... today announced it is a Silver Sponsor of the Digital Workplace Conference, taking ... Centre in Auckland, NZ. Throughout the event, AvePoint will showcase its file analysis, ...
    (Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... that Brian Spector has joined the company as the new Global Communications Director ... broadcasting and public relations experience having spent the last 16 years doing on-air ...
    (Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 ... ... that Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical ... cosmeceutical and skin care experience having spent the last 25 years working in ...
    Breaking Medicine News(10 mins):Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 3Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 4Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2
    ... As ... be welcoming world leaders to the David L. Lawrence Convention Center, the largest "green" ... Design) certification. , ... Pittsburgh, Pa. (PRWEB) September 24, 2009 -- As the industry leader in automatic door ...
    ... , , , SEATTLE, ... launched the Living Proof Project: U.S. Investments in Global Health ... success of the U.S. government,s efforts to improve health around ... Project will show that U.S.-supported initiatives to fight malaria, AIDS, ...
    ... , , , INDIANAPOLIS, ... District of Indiana today upheld Eli Lilly and Company,s (NYSE: ... tablets). In the case of Eli Lilly and Company ... favor of Lilly on all accounts for these method-of-use patents, ...
    ... , , , ... Northern Ireland, moderated by President Clinton, featured Peter Robinson, first ... Northern Ireland Executive; Declan Kelly, economic envoy to Northern Ireland, ... Northern Ireland; and Micheal Martin, Minster of Foreign ...
    ... Sept. 23 Allowing age adjustments more restrictive than 5 to ... in the individual insurance market, making coverage unaffordable for many according ... Cross and Blue Shield Association (BCBSA) released today new data, prepared ... that a 2 to 1 age rating ratio would increase premiums ...
    ... NEW YORK, Sept. 23 The Michael J. ... to successfully translate neurotrophic factor advances from pre-clinical and early-phase ... The funding will be awarded under a new Directed ... , , The Foundation,s intention is to ...
    Cached Medicine News:Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 2Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 3Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 2Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 2Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 4Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 5Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 6Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 7Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 8Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 9Health News:Analysis Shows Narrow Age Rating Would Raise Premiums by Nearly 50 Percent, Causing Many Young and Healthy to Forgo Coverage 2Health News:Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment 2
    ... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
    ... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
    ... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
    ... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
    Medicine Products: